Connect with us

News

Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy

gbafNews28

Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of the PRESTO study by ENETS, and its simultaneous publication in the peer-reviewed journal, Advances in Therapy.1

PRESTO was a multi-national, multi-center, prospective, non-interventional, simulated-use study that enrolled 90 nurses with ‰¥ 2 years experience injecting with the lanreotide (Somatuline Depot) syringe and/or the syringe for long-acting release octreotide. The primary objective of the PRESTO study was to assess nurse preference between the redesigned Somatuline Depot syringe and the syringe for long-acting release octreotide after performing injections into injection pads.

The PRESTO study incorporated an anonymous, web-based questionnaire, where nurses reported their overall preference. Virtually all participants (97.8%) expressed a preference (85.6% strong, 12.2% slight) for the redesigned Somatuline Depot syringe versus the octreotide syringe. Comparative safety and efficacy between Somatuline Depot and octreotide were not evaluated in this study.

“The experiences, attitudes and knowledge of both patients and healthcare practitioners, including nurses, was essential in the redesign of the syringe,” said Daphne T. Adelman, Clinical Nurse Specialist from Northwestern University in Chicago, and a lead author on the PRESTO study. “In the absence of head-to-head trials, these data give healthcare professionals important insights. The ENETS poster presentation and the Advances in Therapy publication of the PRESTO study provide further details on the benefits of the redesigned syringe.”

Indications for Somatuline Depot include the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy; and the long-term treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Please see Important Safety Information below and accompanying full Prescribing Information.

The redesigned Somatuline Depot syringe was developed based on feedback from physicians, nurses and patients;2 and the PRESTO study, for the first time, demonstrates the nurses preference for it versus the octreotide syringe, said Tamer Garawin, M.D., Vice President, Medical Affairs Oncology at Ipsen Biopharmaceuticals. PRESTO is an example of how Ipsen continues our commitment to partnering with patients and healthcare providers, especially nurses, who play a key role in the management of GEP-NETs and acromegaly.

In addition to the PRESTO study, Ipsen had a record 12 abstracts accepted by ENETS.

*ABOUT PRESTO

PRESTO was a randomized, multinational, multicenter, noninterventional, simulated-use study involving nurses (n=90) with experience injecting with the Somatuline Depot syringe and/or the syringe for long-acting release octreotide. The primary objective of this study was to assess preferences of nurses between injecting with the Somatuline Depot syringe and the syringe for long-acting release octreotide. Nurses attended a single testing session, during which they injected injection pads with each type of syringe twice before reporting their preferences. Data were collected using an anonymous, self-administered, web-based questionnaire. Limitations of this study included the need for a change in injection pad after 10 injection sessions due to clogging issues which resulted in two separate cohorts, and that the injections performed were simulated. There were imbalances noted in sociodemographics and clinical setting of nurses which potentially introduces biased reporting of preferences. Another limitation was that some nurses were recruited from the CRO (Contract Research Organization) network organizing the study. This study was not designed to evaluate the efficacy or safety of Somatuline Depot or long-acting release octreotide and no assessment of efficacy or safety should be interpreted based on this study.

ABOUT NETs

A neuroendocrine tumor (NET) begins in the hormone-producing cells of the bodys neuroendocrine system, which is made of cells that are a combination of hormone-producing endocrine cells and nerve cells.3 NETs are a group of uncommon tumors occurring in both men and women aged 50 to 60 years oldalthough they can affect anyone of any age.3

The three main areas where NETs are found in the body are the gastrointestinal tract, the pancreas and the lungs.3

  • Gastrointestinal NETs (GEP-NETs) are found in the gastrointestinal tract or digestive system and are the most common type of NETs.3
  • Pancreatic NETs (pNETs) are formed in the islet cells of the pancreas and include several uncommon types of NETs.3
  • Lung NETs are less common than other types, accounting for about one quarter of NETs.3

The symptoms of NETs are often not distinct and difficult to identify, and average time from initial onset of symptoms to proper diagnosis can take more than 5 years.4 Although NETs affect only a small percentage of the general population at any one time, the number of people being newly diagnosed with NETs overall is believed to be rising.3 This is mainly due to increased awareness of the condition and diagnostic testing.3 NETs are now the fastest growing class of cancers worldwide, accounting for around 2% of all cancers at any time.3

ABOUT ACROMEGALY

Acromegaly is an uncommon hormonal or endocrine disorder with slowly developing, but eventually distinct clinical symptoms.5 In the U.S., approximately 3,500 new cases of acromegaly are diagnosed each year.6

It is usually caused by having too much growth hormone in the body which, over time, results in some characteristic symptoms and signs, such as heavy or prominent facial features with a prominent jaw line and enlarged hands and feet.5

What is SOMATULINE DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

  • the long-term treatment of people with acromegaly when surgery or radiotherapy have not worked well enough or a patient is unable to have surgery or radiotherapy;
  • the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
  • the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

  • Do not take SOMATULINE DEPOT if you are allergic to lanreotide.
  • SOMATULINE DEPOT may cause serious side effects, including:
    • Gallstones
    • Changes to your blood sugar (high or low blood sugar),
    • Slow heart rate,
    • High blood pressure, and
    • Changes in thyroid function in acromegaly patients.
  • Tell your healthcare provider (HCP) if you have any of the following symptoms:
    • Symptoms of gallstones may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.
    • Symptoms of high blood sugar may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.
    • Symptoms of low blood sugar may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
    • Symptoms of slow heart rate may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory problems, and weakness or extreme tiredness.
    • SOMATULINE DEPOT can cause the thyroid gland to not make enough thyroid hormone in people with acromegaly. Symptoms of low thyroid levels may include fatigue, weight gain, puffy face, being cold all the time, constipation, dry skin, thinning or dry hair, decreased sweating, and depression.
  • The most common side effects of SOMATULINE DEPOT in people with:
    • Acromegaly: diarrhea; stomach (abdominal) pain; nausea; and pain, itching, or a lump at the injection site
    • GEP-NETs: stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
    • Carcinoid syndrome: headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs
  • SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.
  • Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.
  • Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you: have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.
  • Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.
  • Especially tell your HCP if you take:
    • Insulin or other diabetes medicines,
    • A cyclosporine (Gengraf, Neoral, or Sandimmune), or
    • Medicines that lower your heart rate, such as beta blockers.

Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

It is not known if SOMATULINE DEPOT is safe and effective in children.

Please see full Prescribing Information, including Patient Information

About Ipsen in North America

Ipsen (Euronext: IPN; ADR: IPSEY) is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes innovative medicines in three key therapeutic areas “ Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsens North American operations are located in Cambridge, Massachusetts, one of the companys three global hubs. Based in the heart of Kendall Square, our fully integrated biopharmaceutical business includes Commercial, Research & Development, Manufacturing, and Global External Innovation and Partnering. Combined with our Canadian headquarters in Mississauga, Ontario, and other locations, Ipsen employs approximately 600 people in North America. For more information please visit www.ipsenus.com or www.ipsen.ca Connect with us on Twitter and LinkedIn.

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Groups management strategy, current views and assumptions. The statements here reflect the outcome of a small simulated study and it is uncertain whether the outcome can be extrapolated to the general nurse or healthcare population. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Groups future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes”, “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Groups expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Groups patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Groups activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Groups partners could generate lower revenues than expected. Such situations could have a negative impact on the Groups business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Groups business is subject to the risk factors outlined in its registration documents filed with the French Autorit des Marchs Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Groups 2018 Registration Document available on its website (www.ipsen.com).

References

  1. Adelman D et al. Adv Ther 2020 Mar 11. doi:10.1007/s12325-020-01255-8
  2. Data on File
  3. Oronsky, B, Ma, PC, Morgensztern, D & Carter, CA et al (2017). Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 19(12):991-1002.
  4. Modlin, IM, Moss, SF, Chung, DC, Jensen, RT, & Snyderwine E (2008). Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors. Journal of the National Cancer Institute, 100, 1282-1289.
  5. Acromunity: Acromegaly information and support. Available at: https://www.acromunity.com [Accessed March 2019].
  6. Burton et al (2016). Incidence and prevalence of acromegaly in a large US health plan. Database. Pituitary.19:262“267.

SOMATULINE DEPOT is a registered trademark of IPSEN PHARMA S.A.S.

All other trademarks and registered trademarks are property of their respective owners.

2020 Ipsen Biopharmaceuticals, Inc.

March 2020 SMD-US-003889

Maryann Quinn

Director, Product Communications

857-529-1151

[email protected]

News

Millennials Now Saving More Money Than Their Parents According to Zip

gbafNews28

SYDNEY, Feb. 27, 2021 /PRNewswire/ — Millennials are a diverse group, the youngest of which is turning 25 this year, while the oldest is nearing 40. In this stage of their lives, financial decisions are increasingly impacted by the fear they won't be able to achieve material goals. The worry is that they won't be able to meet key financial goals, such as buying property, paying back student debt, or saving for retirement.

The differing money-related behaviours of millennials compared to their parents have resulted in their ability to save more. By putting their money into savings accounts, exploring investment plans, and choosing smart financial technology services, millennials are setting the foundation for a strong financial future.

Faced with the risk of being unable to land their dream job, buy a house, or retire until much later in life than their parents did, millennials are choosing to delay homeownership, cutting back on alcohol, spending more on public transport and choosing interest-free payment options wherever possible.

One of the reasons why millennials favour interest-free, online services such as Zip is for their ability to help with budgeting. The millennial crowd are known to manage their finances closely with the help of new technology. Almost 1 in 3 millennials use online tools to track their spending and 7% make use of budgeting apps.

Millennials are also turning away from credit cards in favour of using Buy Now Pay Later apps to manage their finances responsibly, and as a cheaper alternative to credit cards. They also try not to incur interest through unpaid balances unless absolutely necessary, making interest-free BNPL providers a popular choice for this demographic.

Millennials have come of age during a time of economic disruption, technological change and accelerated globalisation. This has given them a set of behaviours and experiences vastly different from their parents. Their unique experiences will change the ways we buy and sell, forcing companies to examine how they do business now and into the future.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/millennials-now-saving-more-money-than-their-parents-according-to-zip-301236400.html

SOURCE Zip

Continue Reading

News

Unique French-English bilingual programme at the Canadian International School (CIS) expanding from August 2021

gbafNews28

SINGAPORE – Media OutReach – 22 February 2021 – The Canadian International School (CIS) in Singapore is delighted to announce the expansion of its unique French-English bilingual programme at the Lakeside campus with the opening of a class in grade 1, 2 and 5 starting in August 2021. Going forward, the programme will now be available to students at its Lakeside campus from grade 1 through to grade 5.

“We are extremely excited about the programme’s expansion as we are the only international school in Singapore to offer a French-English bilingual program fully aligned to the International Baccalaureate PYP framework, ” says CIS Head of School Pete Corcoron. “We are delighted students can now take advantage and enjoy the programme’s unique benefits for a longer period.”

The decision to open up an additional class underscores CIS’ reputation as one of the most experienced and trusted international schools in Singapore to offer bilingual programmes. In addition to CIS’s French-English bilingual programme they also offer a Chinese-English bilingual programme for students in junior kindergarten to grade 6.

The French-English bilingual programme objective

To educate students to become bilingual, biliterate and bicultural in both French and English.

Key features of the French-English bilingual programme

Each class has two qualified teachers — one English speaker and one French speaker. Instruction is inquiry-based and fully aligned to the International Baccalaureate Primary Years Programme (IB PYP). Students have equal exposure to both languages — classes are in English one day and French the next.

CIS’ teaching approach

All learning is done through inquiry. Wherever possible, CIS uses authentic materials (such as songs, stories, TV and websites) instead of textbooks, and engage students in active, hands-on activities like acting out plays, cooking and participating in quizzes. The school places a strong emphasis on creating authentic experiences where learning mirrors real-life activities. CIS don’t do any translating. All learning is done through immersion.

Who can enrol?

While language requirements do apply, CIS welcomes students from all backgrounds. Some students are French native-speakers while others have been educated in a French-speaking school or have a strong connection and passion for the French language.

Continue Reading

News

Nexstgo comprehensively enhances its range of NEXSTMALL BIZ business solutions

gbafNews28

Giving impetus to the development of SMEs with digital strategies to maintain their competitiveness under the ‘new normal’

 

HONG KONG SAR – Media OutReach – 22 February 2021 – As a developer and service provider of innovative digital and technology products, Nexstgo provides PCs, loT innovations, Artificial Intelligence application solutions, Information Technology solutions and more. Stepping into the new year, the “new normal” commercial environment continues to affect business IT purchasing decisions. In order to help SMEs be successful in their digital transformation and adapt to the new reality of remote working, Nexstgo has enhanced its business solutions available through the NEXSTMALL BIZ platform to provide a more comprehensive technology application strategy focusing on the business and commercial field. These include one-stop professional IT services, remote conferencing and VPN security systems, together with a wide range of branded NEXSTGO, VAIO and AVITA mobile computing products. Nexstgo ensures enterprises of any size and industry can find the most suitable software and hardware solutions on NEXSTMALL BIZ, helping businesses maintain the strongest performance under the continuously transforming business environment during the new year.

For more information on NEXSTMALL BIZ business solutions and exclusive offers for corporate clients, please visit:

https://www.nexstmall.com/collections/nexstmall-business-solution

Comprehensively monitoring the network security of customers, providing the most robust backing of IT consulting services at any time

With the routinization of “new normal” working practices, remote-work, WFH, online and cloud-based processes have become ubiquitous. Nexstgo has launched technological solutions specifically for network security management, including the installation of bank-level encryption software by Norton VPN for customers in business areas that require remote-work with a high level of integrated protection. When customers access the Internet on public Wi-Fi hotspots, these systems provide safe and effective online privacy. With the Veeam data encryption backup system, customers can work in any environment confidently. To enhance provision of security technology strategies, the company is also launching further products on NEXSTMALL BIZ, including the latest Targus Docking Station, which supports multiple USB interfaces and screen configurations; Targus Privacy Screen Filter, designed to protect high-value information; and Targus Security Cable Lock that locks the connection end of the transmission line to protect valuable resources on the device. Corporate clients who purchase designated VAIO notebooks on NEXSTMALL BIZ will also get the above-mentioned products and other valuable accessories designed to protect their business privacy. This enables customers to experience the most secure workflows, ensuring business privacy of the whole organization in the era of digital commerce.

As a strategic partner to SMEs, Nexstgo’s elite team also provides customers with professional IT support and technology operation consulting services, helping companies confidently achieve digital transformation and adapt to the “new normal”. These supporting services undertaken by the professional specialist team handle inquiries regarding computer products and software systems, and provide product management and technical support. Customers who purchase any NEXSTGO or VAIO laptop on NEXSTMALL BIZ with a subscription to a one-month IT support service will receive one-time free Data Migration support, allowing corporate clients worry-free activation of new computer equipment without affecting daily operations. Customers benefit from the strongest backing brought by the Nexstgo team whenever they need it, for peace-of-mind and smooth business operations ensuring productivity and performance.

Up-to-date video conferencing and mobile communication solutions: easily connect with customers online, anytime and anywhere

Understanding that many companies and employees have adapted to working at home or working without a fixed workplace, Nexstgo provides online and video conference software and hardware; such as NEXSTGO laptop products with dedicated functionality for online meetings equipped with a high-quality Dolby voice system, and Artificial Intelligence camera lens Huddly-IQ designed for remote video conferencing, etc. This offering provides the most accurate facial recognition and the clearest sound and picture performance, helping customers complete meetings more productively. NEXSTMALL BIZ also offers combination packages of software/hardware available at discounted rates. For example, customers can redeem a Huddly-IQ lens at a discounted price when purchasing a designated VAIO laptop; get 3-year on-site warranty and Jabra headset for free when purchasing a NEXSTGO SU03 laptop, a conference-specific model with FHD IR webcam and Dolby ATMOS. The choice of different combinations of software and hardware help managers select the most effective process strategies according to their business needs.

Nexstgo recognizes that companies must be able to achieve instant interaction and clarity of communication with customers as a key to being competitive. Therefore, Nexstgo has collaborated with outstanding customer service cloud platforms to launch cooperative business solutions. For example, corporate clients who buy any NEXSTGO or VAIO laptop on NEXSTMALL BIZ can enjoy a free service trial of customer interaction at Maaiiconnect platform, including free conversations with end customers on its platform for up to 5000 minutes and real-time web conversations. The package helps companies of all sizes to deliver excellent customer service, and to keep pace with fast-changing business environments. By taking advantage of these solutions and transforming into an e-commerce business – with the realities of the ‘new normal’ replacing traditional face-to-face service – companies can greatly increase their revenues, productivity and cost management performance.

About Nexstgo Company Limited

Established in 2016, Nexstgo Company Limited was co-founded by Mr. Wilson Leung, Chairman & CEO, Alco Holdings Limited (SEHK: 0328), and Mr. Alex Chung, out of a shared passion and pursuit of quality tech-innovation. Nexstgo is committed to bringing new revolutionary experiences in technology through introducing a wide product range, which includes PC, Smart home, IoT, artificial intelligence and corporate solutions. Nexstgo is growing steadily in the Asia Pacific region. In August 2016, its Hong Kong headquarters and Taiwan Design Centre were set up. In just four years, the company has expanded its business to 22 areas, and is fully committed to the development of the Tech Market. In June 2018, Nexstgo was authorized by VAIO Corporation to participate in the production, sales, marketing and after-sales services of VAIO notebook products in Asia, covering markets such as Hong Kong, Taiwan, Macau, Malaysia and Singapore.

www.nexstgo.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News25 mins ago

Millennials Now Saving More Money Than Their Parents According to Zip

SYDNEY, Feb. 27, 2021 /PRNewswire/ — Millennials are a diverse group, the youngest of which is turning 25 this year, while...

gbafNews28 gbafNews28
News34 mins ago

Unique French-English bilingual programme at the Canadian International School (CIS) expanding from August 2021

SINGAPORE – Media OutReach – 22 February 2021 – The Canadian International School (CIS) in Singapore is delighted to announce...

gbafNews28 gbafNews28
News34 mins ago

HKGSEO Provides Free Website SEO Analysis and Consulting Services

HONG KONG SAR – Media OutReach – 22 February 2021 – The COVID-19 epidemic has lasted for nearly a year....

gbafNews28 gbafNews28
News34 mins ago

Media OutReach Expands into China with Strategic Partnership with Xinhua Finance Agency

The newswire continues growing its foothold in Asia by opening its 7th office in the region   HONG KONG SAR...

gbafNews28 gbafNews28
News34 mins ago

Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

HONG KONG SAR – Media OutReach – 22 February 2021 – This announcement is made by Ocumension Therapeutics (the “Company“,...

gbafNews28 gbafNews28
News34 mins ago

Citi Plus® Official Launch Ceremony

HONG KONG SAR – Media OutReach – 22 February 2021 Photo 1 Mr Lawrence Lam, Consumer Business Manager of Citibank...

gbafNews28 gbafNews28
News34 mins ago

Hong Kong Productivity Council and Hong Kong Computer Society Sign Pact to Enhance the Adoption of Emerging Technologies in Hong Kong

HONG KONG SAR – Media OutReach – 22 February 2021 – The Hong Kong Productivity Council (HKPC) and the Hong...

gbafNews28 gbafNews28
News34 mins ago

Citibank Officially Launches Citi Plus®

Co-creating With Target Clients to Suit Their Banking and Investment Needs Fostering Financial Education to Level-Up Digital Natives Through Mobile...

gbafNews28 gbafNews28
News34 mins ago

Kerry Logistics Network Extends Winning Streak at the Quamnet Outstanding Enterprise Awards for Sixth Year Running

HONG KONG SAR – Media OutReach – 22 February 2021 – Kerry Logistics Network Limited (‘Kerry Logistics Network’; Stock Code...

gbafNews28 gbafNews28
News34 mins ago

Black Spade Capital Aims to Build an SPAC-themed Portfolio

HONG KONG SAR – Media OutReach – 22 February 2021 – 2020 proved to be a great year for Special...